

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA [Dapagliflozin in combination therapy for the treatment of type 2 diabetes]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Issue 1

As dapagliflozin works through elimination via the kidneys, if this has a bearing on kidney function, it is important to note the higher prevalence of established renal failure in African Caribbean and South Asian communities, and that kidney disease may progress more rapidly to established renal failure in people from these communities.

Issue 2

NICE clinical guideline no. 87 states that for patients of non-European descent (African, South Asian or Caribbean), the body mass index (BMI) threshold for treatment with GLP-1 agonists is adjusted downward, as they are at higher risk of developing type 2 diabetes. A similar adjustment is recommended for these ethnic groups in the NICE guidance for liraglutide (technology appraisal no. 203) and exenatide prolonged release (technology appraisal no. 248).

The manufacturer of dapagliflozin has indicated that a separate economic analysis for South Asian, African or Caribbean patients will not be presented in the submission to NICE but a lower BMI threshold should still apply given their increased risk and consequent increased opportunity to gain benefit from treatment at lower BMIs.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issue 1

The manufacturer indicated at the scoping workshop that dapagliflozin would not be licensed for use in people who had renal failure and that these people were not included in the clinical trials. It was therefore considered that this is not an equality issue.

Issue 2

The Committee will consider this issue during the course of the appraisal and will ensure that any recommendation related to BMI would not jeopardize the commitment of NICE to promoting equality of opportunity.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Janet Robertson

Date: 18th May 2012